Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension (BETTER-HTN)
Recruitment status was Recruiting
To determine whether impedance cardiography (ICG) parameters can predict favorable or unfavorable blood pressure (BP) response and time to BP control prior to initiation or intensification of specific antihypertensive drug classes and drug combinations, independent of initial BP levels.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension (BETTER-HTN)|
- To determine if ICG can predict therapeutic response to antihypertensive medications [ Time Frame: 2009-2010 ] [ Designated as safety issue: No ]
- To confirm derivation phase of ICG prediction to therapeutic response of antihypertensive medications. [ Time Frame: 2010-2011 ] [ Designated as safety issue: No ]
|Study Start Date:||January 2009|
|Estimated Study Completion Date:||June 2011|
|Estimated Primary Completion Date:||January 2011 (Final data collection date for primary outcome measure)|
Group will have results blinded during observational phase of study. Results will be revealed at time of testing during the validation phase of the study.
- Patients with higher vascular resistance index and/or lower arterial compliance index will lower BP faster and to a greater degree overall when receiving vasodilating agents - such as ACEI's, ARB's, dihydropyridine CCB's, direct vasodilators, and central alpha agonists.
- Patients with an elevated cardiac index will lower BP faster and to a greater degree overall when receiving agents that reduce contractility, heart rate, or blood volume - such as beta blockers, non-dihydropyridine CCB's, and other agents that are known to reduce cardiac index.
- Patients with an elevated thoracic fluid content or lower orthostatic change in thoracic fluid content will lower BP faster and to a greater degree overall when receiving diuretics (thiazide, loop, potassium sparing), however - one of these agents will emerge as a superior alternative to reduce BP in patients with high thoracic fluid content / low orthostatic change in thoracic fluid content.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00913094
|United States, Michigan|
|Wayne State University||Recruiting|
|Detroit, Michigan, United States, 48201|
|Contact: Mary Maysura 313-745-2378|
|Principal Investigator: John Flack, MD|
|Principal Investigator:||John M Flack, MD||Wayne State University, and Detroit Medical Center|